SEARCH

SEARCH BY CITATION

References

  • 1
    Smith ND. Quality of life studies from the perspective of an FDA reviewing statistician. DIA J 1993; 27:617 23.
  • 2
    Medical Outcomes Trust. Asthma quality of life assessment in pharmaceutical research. Med Outcomes Trust Bull 1997;5:1 2.
  • 3
    Oleson M. Subjectively perceived quality of life. Image 1990;22:187 90.
  • 4
    Shumaker SA & Berzon RA (eds.). The International Assessment of HRQL. Theory, Translations, Measurement and Analysis. Oxford: Rapid Communications, 1995.
  • 5
    Meinhart CL & Tonascia S. Clinical Trials Design, Conduct, and Analysis. New York: Oxford University Press, 1986.
  • 6
    Osoba D. Rationale for the timing of health-related quality-of-life assessments in oncological palliative therapy. Cancer Treat Rev 1996;22 (Suppl. A):69 73.
  • 7
    Osoba D. Guidelines for measuring health-related quality of life in clinical trials. In: StaquetMJ, HaysRD, FayersPM (eds.). Quality of Life Assessment in Clinical Trials: Methods and Practice. New York: Oxford University Press, 1998.
  • 8
    Bonomi A, Legro M, Leidy NK, Zyczynski T, McGann M, Ajax M. Maximizing quality in quality of life outcomes research: a multi-faceted approach for clinical trials. Quality Life Res 1998;7:574.
  • 9
    Patrick DL & Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27(Suppl. 3):S217 32.
  • 10
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.
  • 11
    Bergner MB, Bobbitt RA, Carter WB, Gilson BS. The SIP: development and final revision of a health status measure. Med Care 1981;19:787 805.
  • 12
    Hunt SM, McEwan J, McKenna SP. Measuring Health Status. London: Croom Helm, 1986.
  • 13
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for the Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 1993;85:365 76.
  • 14
    Osoba D. Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology. Cancer Treat Rev 1993;19(Suppl. A):1 9.
  • 15
    Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis 1984;37:85 95.
  • 16
    Kaplan RM, Anderson JP, Wu AW, et al. The Quality of Well-Being Scale: applications in AIDS, cystic fibrosis, and arthritis. Med Care 1989;27 (Suppl. 3):S27 S43.
  • 17
    Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions: Health Utilities Index. Pharmacoeconomics 1995;7:503 20.
  • 18
    Feeny D, Torrance GW, Furlong W. Health Utilities Index. In: SpilkerB (ed.). Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed.). New York: Raven-Lippincott Press, 1996.
  • 19
    Kind P. The EuroQol instrument: an index of health related quality of life. In: SpilkerB (ed.). Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed.). New York: Raven-Lippincott Press, 1996.
  • 20
    Lewis C, Pantell R, Kieckhefer G. Assessment of children’s health status: field test of new approaches. Med Care 1989;27(Suppl.):S54 S65.
  • 21
    Rothman ML, Hedrick SC, Bulcroft KA, et al. The validity of proxy-generated scores as measures of patient health status. Med Care 1991;29:115 24.
  • 22
    Sigurdardottir V, Brandberg Y, Sullivan M. Criterion-based validation of the EORTC QLQ-C36 in melanoma: the CIPS questionnaire and proxy raters. Qual Life Res 1996;5:375 86.
  • 23
    Sneeuw KCA, Aaronson NK, Osoba D, et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care 1997;35:490 506.
  • 24
    Gold MR, Siegel JE, Russell LB, Weinstein MC (eds.). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 25
    Nunnally JC & Bernstein IH. Psychometric Theory (3rd ed.). New York: McGraw-Hill, 1994.
  • 26
    American Psychological Association. Standards for Educational and Psychological Tests. Washington, DC: American Psychological Association, 1985.
  • 27
    Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol 1992;45:1341 5.
  • 28
    Hays R, Anderson R, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: StaquetMJ, HaysRD, FayersPM (eds.). Quality of Life Assessment in Clinical Trials. New York: Oxford University Press, 1998.
  • 29
    Lohr KN, Aaronson NK, Alonso J, et al. Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 1996;18:979 92.
  • 30
    Revicki DA & Ehreth JL. Health-related quality of life assessment and planning for the pharmaceutical industry. Clin Ther 1997;19:1101 15.
  • 31
    Leidy NK, Rentz A, Grace E. Evaluating health-related quality of life outcomes in clinical trials of anti-epileptic therapy. Epilepsia 1998;39:965 77.
  • 32
    Hui C & Triandis HC. Measurement in cross-cultural psychology: a review and comparison of strategies. Cross Cultural Psychol 1985;16:131 5.
  • 33
    Bullinger M, Anderson R, Cella D, Aaronson N. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res 1993;2:451 9.
  • 34
    Hunt SM. Cross-cultural issues in the use of quality of life measures in randomized clinical trials. In: StaquetMJ, HaysRD, FayersPM (eds.). Quality of Life Assessment in Clinical Trials: Methods and Practice. New York: Oxford University Press, 1998.
  • 35
    Leidy NK, Chan K, Coughlin C. Is the Asthma Quality of Life Questionnaire (AQLQ) a useful indicator of health-related quality of life in low-income samples? Am J Respir Crit Care Med 1998;158:1082 90.
  • 36
    Leidy NK & Coughlin C. Psychometric performance of the Asthma Quality of Life Questionnaire (AQLQ) in a U.S. Sample. Qual Life Res 1998;7: 127 34.
  • 37
    Leidy NK, Elixhauser A, Rentz A, William M, Beach R, Pellock J, Schachter S. Telephone validation of the Quality of Life in Epilepsy Inventory (QOLIE-89). Epilepsia 1999;40(1):97 106.
  • 38
    Berzon RA. Understanding and using HRQL instruments within clinical research studies. In: StaquetMJ, HaysRD, FayersPM (eds.). Quality of Life Assessment in Clinical Trials. Oxford: Oxford University Press, 1998.
  • 39
    Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston: The Health Institute, New England Medical Center, 1994.
  • 40
    Devinsky O, Vickrey BG, Cramer J, et al. Development of the Quality of Life in Epilepsy Inventory. Epilepsia 1995;36:1089 104.
  • 41
    Simon GE, Revicki DA, Grothaus L, VonKorff M. SF-36 summary scores: are physical and mental health truly distinct? Med Care 1998;36:567 72.
  • 42
    Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the MOS HIV Health Survey. Med Care 1998;36:126 37.
  • 43
    Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-life assessment in clinical trials. In: ScheurlenH, KayR, BaumM (eds.). Cancer Trials: A Critical Appraisal. Berlin: Springer, 1988.
  • 44
    Wu AW, Rudin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991; 29:786 98.
  • 45
    Testa MA & Nackley JF. Methods for quality-of-life studies. Ann Rev Public Health 1994;15:535 59.
  • 46
    O’Brien P. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079 87.
  • 47
    Pocock SJ, Geller NL, Tsiatis A. The analysis of multiple endpoints in clinical trials. Biometrics 1991;43:487 98.
  • 48
    Wei LJ & Johnson WE. Combining dependent tests with incomplete repeated measurements. Biometrika 1985;72:359 64.
  • 49
    Zee BC. Growth curve model analysis for quality of life data. Statistics Med 1998;17:757 66.
  • 50
    Lemacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling the experiment wise error rate. Biometrics 1991;47:511 21.
  • 51
    Bernhard J, Cella D, Coates A, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Statistics Med 1998;17: 517 32.
  • 52
    Curran D, Fayers PM, Molengerghs G, Machin D. Analysis of incomplete quality of life data in clinical trials. In: StaquetMJ, HaysRD, FayersPM (eds.). Quality of Life Assessment in Clinical Trials. New York: Oxford University Press, 1998.
  • 53
    Fairclough D, Peterson H, Cella D, Bonomi P. Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials. Statistics Med 1998;17:781 96.
  • 54
    Little RJ & Rubin DB. Statistical Analysis with Missing Data. New York: John Wiley & Sons, 1987.
  • 55
    Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997;6:481 93.
  • 56
    Chan K & Revicki DA. Changes in surrogate laboratory markers, clinical endpoints and health-related quality of life in patients infected with the human immunodeficiency virus. Eval Health Profess 1998; 21:265 81.
  • 57
    Coates AS, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian–New Zealand Breast Cancer Trials Group. J Clin Oncol 1992;10:1833 8.
  • 58
    Coates A, Porzsolt F, Osoba D. Quality of life in Oncology Practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997;33:1025 30.
  • 59
    Dancey J, Zee B, Osoba D, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 1997;6:151 8.
  • 60
    Testa MA, Hollenberg NK, Anderson RB, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am J Hypertens 1991;4:363 73.
  • 61
    Heyting A, Tolboom JTBM, Essers JGA. Statistical handling of dropouts in longitudinal clinical trials. Statistics Med 1992;11:2043 61.
  • 62
    Lavori PW, Dawson R, Shera D. A multiple imputation strategy for clinical trials with truncation of patient data. Statistics Med 1995;14:1913 25.
  • 63
    Revicki DA, Swartz C, Gold K, Kallich J, Woolley M. Imputing health status scores missing due to mortality: comparison of multiple techniques. Qual Life Res 1997;6:708.
  • 64
    Chow SC & Ki F. On statistical characteristics of quality of life assessment. J Biopharm Stat 1994;4: 1 17.
  • 65
    Dwyer JH, Feinleib M, Lippert P, Hoffmeister H (eds.). Statistical Models for Longitudinal Studies of Health. New York: Oxford University Press, 1992.
  • 66
    Ware J. Linear models for the analysis of longitudinal studies. Am Statistician 1992;39:95 101.
  • 67
    Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute, 1996.
  • 68
    Waternaux C & Ware J. Unconditional linear models for analysis of longitudinal data. In: DwyerJH, FeinleibM, LippertP, HoffmeisterH (eds.). Statistical Models for Longitudinal Studies of Health. New York: Oxford University Press, 1992.
  • 69
    Jaeschke R, Singer J, Guyatt GH. Measurements of health status: ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10:407 15.
  • 70
    Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139 44.
  • 71
    King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:555 67.
  • 72
    Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832 8.
  • 73
    Evans RW, Rader B, Manninen DL, Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263:825 30.
  • 74
    Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657 64.
  • 75
    FDA Modernization Act, 1997. Available at: http://www.fda.gov/cder/guidance/105-115.htm#sec.115. Accessed January 7, 1999.
  • 76
    FDA Modernization Act, 1997. Available at: http://www.fda.gov/cder/guidance/105-115.htm#sec.205. Accessed January 7, 1999.
  • 77
    Revicki DA & Cella DF. Health status assessment for the twenty-first century: item response theory, item banking, and computer adaptive testing. Qual Life Res 1997;6:595 600.
  • 78
    McHorney CA. Generic health measurement: past accomplishments and a measurement paradigm for the 21st century. Ann Intern Med 1997;127: 743 50.
  • 79
    Buxton J, White M, Osoba D. Patients’ experiences using a computerized program with a touch-sensitive video monitor for the assessment of health-related quality of life. Qual Life Res 1998; 7:513 9.
  • 80
    Kleinman L, Bonomi A, Legro M, Crawley J. Assessment of health-related quality of life via computer touch screen. Qual Life Res 1998;7:617.